Long-term efficacy and safety of low-dose ritonavir-boosted atazanavir (ATV/r) 200/100 mg in HIV-infected Thai patients

類似資料

• Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial
  著者:: Cooper, David A., 等
  出版事項: (2016)
• Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.
  著者:: Takeshi Nishijima, 等
  出版事項: (2013-01-01)
• Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients
  著者:: Nishijima, Takeshi, 等
  出版事項: (2013)
• Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT
  著者:: Smith, Kimberly Y, 等
  出版事項: (2008)
• Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers
  著者:: Jackson, Akil, 等
  出版事項: (2010)